[{"id":"c5f60531-65fd-4bcb-88b3-780e1307cb1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512182","created_at":"2022-08-23T14:55:32.104Z","updated_at":"2024-07-02T16:35:45.560Z","phase":"Phase 2","brief_title":"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression","source_id_and_acronym":"NCT05512182","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Nerlynx (neratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-06-15"}]